Is RARE or IRD more profitable?

Ultragenyx Pharmaceutical has a net margin of -81.79% compared to Opus Genetics' net margin of -1,091.82%. Company Net Margins Return on Equity Return on Assets Ultragenyx Pharmaceutical -81.79% N/A -44.40% Opus Genetics -1,091.82% N/A -150.13%

Does the media prefer RARE or IRD?

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Opus Genetics. MarketBeat recorded 15 mentions for Ultragenyx Pharmaceutical and 12 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.41 beat Ultragenyx Pharmaceutical's score of 0.24 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 2 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, IRD or ANAB?

AnaptysBio has higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Opus Genetics $14.20M 27.06 -$49.59M -$1.35 N/A AnaptysBio $234.60M 5.86 -$13.23M $5.37 8.56

Is IRD or ANAB more profitable?

AnaptysBio has a net margin of 82.37% compared to Opus Genetics' net margin of -1,091.82%. AnaptysBio's return on equity of 112.00% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Opus Genetics -1,091.82% N/A -150.13% AnaptysBio 82.37% 112.00% 2.20%

Does the media favor IRD or ANAB?

In the previous week, Opus Genetics had 5 more articles in the media than AnaptysBio. MarketBeat recorded 12 mentions for Opus Genetics and 7 mentions for AnaptysBio. Opus Genetics' average media sentiment score of 0.41 beat AnaptysBio's score of 0.23 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is KLRA or IRD more profitable?

Kailera Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Company Net Margins Return on Equity Return on Assets Kailera Therapeutics N/A N/A N/A Opus Genetics -1,091.82% N/A -150.13%

Does the media refer more to KLRA or IRD?

In the previous week, Opus Genetics had 3 more articles in the media than Kailera Therapeutics. MarketBeat recorded 12 mentions for Opus Genetics and 9 mentions for Kailera Therapeutics. Opus Genetics' average media sentiment score of 0.41 beat Kailera Therapeutics' score of 0.18 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kailera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Opus Genetics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TSHA or IRD?

In the previous week, Opus Genetics had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 12 mentions for Opus Genetics and 11 mentions for Taysha Gene Therapies. Opus Genetics' average media sentiment score of 0.41 beat Taysha Gene Therapies' score of 0.40 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, AAPG or IRD?

Opus Genetics has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 16.64 -$177.71M N/A N/A Opus Genetics $14.20M 27.06 -$49.59M -$1.35 N/A

Is AAPG or IRD more profitable?

Ascentage Pharma Group International has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Opus Genetics -1,091.82% N/A -150.13%

Does the media favor AAPG or IRD?

In the previous week, Opus Genetics had 5 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 12 mentions for Opus Genetics and 7 mentions for Ascentage Pharma Group International. Opus Genetics' average media sentiment score of 0.41 beat Ascentage Pharma Group International's score of 0.11 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascentage Pharma Group International 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Opus Genetics (IRD) Competitors

$4.65 +0.19 (+4.26%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.68 +0.03 (+0.67%)

As of 10/9/2026 07:49 PM Eastern

Compare

IRD vs. RARE, ANAB, KLRA, TSHA, and AAPG

Should you buy Opus Genetics stock or one of its competitors? Opus Genetics's main competitors and comparable companies include Ultragenyx Pharmaceutical (RARE), AnaptysBio (ANAB), Kailera Therapeutics (KLRA), Taysha Gene Therapies (TSHA), and Ascentage Pharma Group International (AAPG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Opus Genetics compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Opus Genetics. MarketBeat recorded 15 mentions for Ultragenyx Pharmaceutical and 12 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.41 beat Ultragenyx Pharmaceutical's score of 0.24 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ultragenyx Pharmaceutical has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Opus Genetics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Opus Genetics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	2.27	-$575M	-$5.84	N/A
Opus Genetics	$14.20M	27.06	-$49.59M	-$1.35	N/A

Ultragenyx Pharmaceutical currently has a consensus target price of $34.58, indicating a potential upside of 123.38%. Opus Genetics has a consensus target price of $12.29, indicating a potential upside of 164.21%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Ultragenyx Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.89

Ultragenyx Pharmaceutical has a net margin of -81.79% compared to Opus Genetics' net margin of -1,091.82%.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-81.79%	N/A	-44.40%
Opus Genetics	-1,091.82%	N/A	-150.13%

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Opus Genetics beats Ultragenyx Pharmaceutical on 9 of the 15 factors compared between the two stocks.

How does Opus Genetics compare to AnaptysBio?

Opus Genetics (NASDAQ:IRD) and AnaptysBio (NASDAQ:ANAB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, Opus Genetics had 5 more articles in the media than AnaptysBio. MarketBeat recorded 12 mentions for Opus Genetics and 7 mentions for AnaptysBio. Opus Genetics' average media sentiment score of 0.41 beat AnaptysBio's score of 0.23 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AnaptysBio	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.0% of Opus Genetics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 31.5% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

AnaptysBio has a net margin of 82.37% compared to Opus Genetics' net margin of -1,091.82%. AnaptysBio's return on equity of 112.00% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	N/A	-150.13%
AnaptysBio	82.37%	112.00%	2.20%

Opus Genetics presently has a consensus target price of $12.29, indicating a potential upside of 164.21%. AnaptysBio has a consensus target price of $77.79, indicating a potential upside of 69.28%. Given Opus Genetics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Opus Genetics is more favorable than AnaptysBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.89
AnaptysBio	1 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.71

AnaptysBio has higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	27.06	-$49.59M	-$1.35	N/A
AnaptysBio	$234.60M	5.86	-$13.23M	$5.37	8.56

Opus Genetics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, AnaptysBio has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Summary

AnaptysBio beats Opus Genetics on 9 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to Kailera Therapeutics?

Kailera Therapeutics (NASDAQ:KLRA) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings, dividends and media sentiment.

15.0% of Opus Genetics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kailera Therapeutics presently has a consensus price target of $42.75, indicating a potential upside of 268.22%. Opus Genetics has a consensus price target of $12.29, indicating a potential upside of 164.21%. Given Kailera Therapeutics' higher possible upside, research analysts clearly believe Kailera Therapeutics is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.89

Opus Genetics has higher revenue and earnings than Kailera Therapeutics. Opus Genetics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A
Opus Genetics	$14.20M	27.06	-$49.59M	-$1.35	N/A

Kailera Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%.

Company	Net Margins	Return on Equity	Return on Assets
Kailera Therapeutics	N/A	N/A	N/A
Opus Genetics	-1,091.82%	N/A	-150.13%

In the previous week, Opus Genetics had 3 more articles in the media than Kailera Therapeutics. MarketBeat recorded 12 mentions for Opus Genetics and 9 mentions for Kailera Therapeutics. Opus Genetics' average media sentiment score of 0.41 beat Kailera Therapeutics' score of 0.18 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kailera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Opus Genetics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Opus Genetics beats Kailera Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Opus Genetics compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Taysha Gene Therapies has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Opus Genetics' return on equity of 0.00% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.19%	-41.84%
Opus Genetics	-1,091.82%	N/A	-150.13%

77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 3.5% of Taysha Gene Therapies shares are held by insiders. Comparatively, 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Opus Genetics has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	149.74	-$109M	-$0.42	N/A
Opus Genetics	$14.20M	27.06	-$49.59M	-$1.35	N/A

Taysha Gene Therapies currently has a consensus target price of $12.77, suggesting a potential upside of 184.39%. Opus Genetics has a consensus target price of $12.29, suggesting a potential upside of 164.21%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Opus Genetics had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 12 mentions for Opus Genetics and 11 mentions for Taysha Gene Therapies. Opus Genetics' average media sentiment score of 0.41 beat Taysha Gene Therapies' score of 0.40 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Taysha Gene Therapies has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Summary

Taysha Gene Therapies beats Opus Genetics on 9 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, Opus Genetics had 5 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 12 mentions for Opus Genetics and 7 mentions for Ascentage Pharma Group International. Opus Genetics' average media sentiment score of 0.41 beat Ascentage Pharma Group International's score of 0.11 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascentage Pharma Group International presently has a consensus price target of $44.75, suggesting a potential upside of 205.88%. Opus Genetics has a consensus price target of $12.29, suggesting a potential upside of 164.21%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.18
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.89

Ascentage Pharma Group International has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Opus Genetics has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	16.64	-$177.71M	N/A	N/A
Opus Genetics	$14.20M	27.06	-$49.59M	-$1.35	N/A

15.0% of Opus Genetics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ascentage Pharma Group International has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Opus Genetics	-1,091.82%	N/A	-150.13%

Summary

Opus Genetics beats Ascentage Pharma Group International on 8 of the 14 factors compared between the two stocks.

Get Opus Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRD vs. The Competition

Export

Metric	Opus Genetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$368.61M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-3.44	13.42	274.15	26.16
Price / Sales	27.06	1,237.85	590.48	94.54
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	21.14	17.17	11.21	6.34
Net Income	-$49.59M	-$22.69M	$3.50B	$381.90M
7 Day Performance	1.53%	-1.33%	-0.90%	-1.41%
1 Month Performance	-23.39%	-8.44%	-4.44%	-3.48%
1 Year Performance	137.24%	14.02%	6.96%	1.16%

Opus Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRD Opus Genetics	3.0828 of 5 stars	$4.65 +4.3%	$12.29 +164.2%	+133.7%	$368.61M	$14.20M	N/A	28	Analyst Forecast Gap Up
RARE Ultragenyx Pharmaceutical	3.0718 of 5 stars	$14.48 +0.1%	$34.58 +138.8%	-51.1%	$1.42B	$673M	N/A	1,371	Analyst Forecast
ANAB AnaptysBio	3.9441 of 5 stars	$47.04 -1.8%	$77.79 +65.4%	+44.6%	$1.41B	$234.60M	8.79	104
KLRA Kailera Therapeutics	2.2173 of 5 stars	$10.83 flat	$42.75 +294.7%	N/A	$1.40B	N/A	N/A	145	Analyst Downgrade Lockup Expiration
TSHA Taysha Gene Therapies	2.5477 of 5 stars	$4.31 -1.9%	$12.77 +196.6%	-10.2%	$1.40B	$9.77M	N/A	99	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRD) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Opus Genetics (IRD) Competitors

IRD vs. RARE, ANAB, KLRA, TSHA, and AAPG

How does Opus Genetics compare to Ultragenyx Pharmaceutical?

Summary

How does Opus Genetics compare to AnaptysBio?

Summary

How does Opus Genetics compare to Kailera Therapeutics?

Summary

How does Opus Genetics compare to Taysha Gene Therapies?

Summary

How does Opus Genetics compare to Ascentage Pharma Group International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Opus Genetics (IRD) Competitors

IRD vs. RARE, ANAB, KLRA, TSHA, and AAPG

How does Opus Genetics compare to Ultragenyx Pharmaceutical?

Does the media prefer RARE or IRD?

Which has more risk and volatility, RARE or IRD?

Which has preferable valuation and earnings, RARE or IRD?

Do analysts rate RARE or IRD?

Is RARE or IRD more profitable?

Do insiders and institutionals have more ownership in RARE or IRD?

Summary

How does Opus Genetics compare to AnaptysBio?

Does the media favor IRD or ANAB?

Do insiders & institutionals have more ownership in IRD or ANAB?

Is IRD or ANAB more profitable?

Do analysts prefer IRD or ANAB?

Which has higher valuation and earnings, IRD or ANAB?

Which has more risk and volatility, IRD or ANAB?

Summary

How does Opus Genetics compare to Kailera Therapeutics?

Do insiders & institutionals believe in KLRA or IRD?

Do analysts recommend KLRA or IRD?

Which has better earnings and valuation, KLRA or IRD?

Is KLRA or IRD more profitable?

Does the media refer more to KLRA or IRD?

Summary

How does Opus Genetics compare to Taysha Gene Therapies?

Is TSHA or IRD more profitable?

Do insiders and institutionals hold more shares of TSHA or IRD?

Which has higher valuation & earnings, TSHA or IRD?

Do analysts rate TSHA or IRD?

Does the media refer more to TSHA or IRD?

Which has more volatility and risk, TSHA or IRD?

Summary

How does Opus Genetics compare to Ascentage Pharma Group International?

Does the media favor AAPG or IRD?

Do analysts recommend AAPG or IRD?

Which has more volatility & risk, AAPG or IRD?

Which has better valuation and earnings, AAPG or IRD?

Do insiders and institutionals have more ownership in AAPG or IRD?

Is AAPG or IRD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools